We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
+13.03%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.67B
AUM Growth
+$502M
Cap. Flow
+$375M
Cap. Flow %
22.44%
Top 10 Hldgs %
57.54%
Holding
148
New
14
Increased
40
Reduced
54
Closed
20

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$70.1M
2
EOLS icon
Evolus
EOLS
+$22.3M
3
RDNW
RideNow Group
RDNW
+$18M
4
ESTA icon
Establishment Labs
ESTA
+$17.1M
5
IWM icon
iShares Russell 2000 ETF
IWM
+$13.6M

Top Sells

Rank Stock Value
1
CASH icon
Pathward Financial
CASH
+$8.58M
2
RH icon
RH
RH
+$5.38M
3
VTYX
Ventyx Biosciences
VTYX
+$5.13M
4
IMTX icon
Immatics
IMTX
+$4.66M
5
MLKN icon
MillerKnoll
MLKN
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 35.39%
2 Consumer Discretionary 8.45%
3 Financials 4.4%
4 Communication Services 3.48%
5 Technology 2.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HURA
126
TuHURA Biosciences
HURA
$142M
$3.73K ﹤0.01%
629
-17
-3% -$879
ADCT icon
127
ADC Therapeutics
ADCT
$145M
– –
-257,162
Closed -$231K
BXMT icon
128
PUT
Blackstone Mortgage Trust
BXMT
$2.45B
– –
-200,000
Closed -$4.35M
CCCC icon
129
C4 Therapeutics
CCCC
$433M
– –
-1,000,000
Closed -$1.86M
DERM icon
130
Journey Medical
DERM
$178M
– –
-348,663
Closed -$955K
ELTX icon
131
Elicio Therapeutics
ELTX
$80.4M
– –
-30,000
Closed -$254K
GYRE icon
132
Gyre Therapeutics
GYRE
$711M
– –
-4,520
Closed -$32.7K
INMD icon
133
PUT
InMode
INMD
$872M
– –
-100,000
Closed -$3.05M
KRE icon
134
PUT
State Street SPDR S&P Regional Banking ETF
KRE
$4.6B
– –
-600,000
Closed -$25.1M
RH icon
135
RH
RH
$3.47B
– –
-20,853
Closed -$5.38M
RDNW
136
CALL
RideNow Group
RDNW
$244M
– –
-200,000
Closed -$1.23M
TBBK icon
137
The Bancorp
TBBK
$2.83B
– –
-24,896
Closed -$859K
TGTX icon
138
TG Therapeutics
TGTX
$7.61B
– –
-150,000
Closed -$1.25M
VTYX
139
DELISTED
Ventyx Biosciences
VTYX
– –
-147,623
Closed -$5.13M
AAN
140
DELISTED
The Aaron's Company Inc
AAN
– –
-138,572
Closed -$1.45M
KRTX
141
CALL
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-30,000
Closed -$5.07M
PNT
142
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-521,191
Closed -$3.48M
NOGNW
143
DELISTED
Nogin, Inc. Warrant
NOGNW
– –
-330,000
Closed -$13.3K
ACER
144
DELISTED
Acer Therapeutics Inc
ACER
– –
-918,349
Closed -$748K
AKU
145
DELISTED
Akumin Inc
AKU
– –
-979,196
Closed -$143K
NOGN
146
DELISTED
Nogin, Inc. Common Stock
NOGN
– –
-56,425
Closed -$30K
2 3 4 5
6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Nantahala Capital Management held 148 positions worth $1.67B, up 43% from $1.17B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Nantahala Capital Management deployed $375M of net new capital in Q4 2023, opening 14 new positions and adding to 40 existing holdings. Its largest new stake was Abivax: 1,010,034 shares worth $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 36% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Pathward Financial, an estimated $8.58M trimmed.

  • Nantahala Capital Management's largest Q4 2023 buy was Abivax: 1,010,034 shares worth $10.8M.
  • Nantahala Capital Management added most to Soleno Therapeutics in Q4 2023, an estimated $70.1M increase.
  • Nantahala Capital Management's biggest Q4 2023 reduction was Pathward Financial, cutting an estimated $8.58M.
  • Nantahala Capital Management fully exited RH in Q4 2023, selling an estimated $5.38M.
  • Nantahala Capital Management's ten largest holdings make up 58% of its $1.67B portfolio in Q4 2023.
  • Nantahala Capital Management opened 14 new positions and closed 20 in Q4 2023.
  • Nantahala Capital Management's portfolio value rose 43% quarter-over-quarter to $1.67B.

Based on Nantahala Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.